10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
9.25
-0.20 (-2.12%)
Jun 3, 2025, 1:40 PM - Market open

10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of $1.14 billion. The enterprise value is $779.23 million.

Market Cap 1.14B
Enterprise Value 779.23M

Important Dates

The last earnings date was Thursday, May 8, 2025, after market close.

Earnings Date May 8, 2025
Ex-Dividend Date n/a

Share Statistics

10x Genomics has 123.13 million shares outstanding. The number of shares has increased by 2.66% in one year.

Current Share Class 111.09M
Shares Outstanding 123.13M
Shares Change (YoY) +2.66%
Shares Change (QoQ) +0.83%
Owned by Insiders (%) 8.27%
Owned by Institutions (%) 89.47%
Float 109.00M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.83
Forward PS 1.79
PB Ratio 1.65
P/TBV Ratio 1.64
P/FCF Ratio 24.82
P/OCF Ratio 19.85
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.25
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 17.18

Financial Position

The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.11.

Current Ratio 5.37
Quick Ratio 4.44
Debt / Equity 0.11
Debt / EBITDA n/a
Debt / FCF 1.77
Interest Coverage -60,529.67

Financial Efficiency

Return on equity (ROE) is -22.03% and return on invested capital (ROIC) is -14.20%.

Return on Equity (ROE) -22.03%
Return on Assets (ROA) -12.43%
Return on Invested Capital (ROIC) -14.20%
Return on Capital Employed (ROCE) -22.83%
Revenue Per Employee $478,302
Profits Per Employee -$120,242
Employee Count 1,306
Asset Turnover 0.68
Inventory Turnover 2.50

Taxes

In the past 12 months, 10x Genomics has paid $3.63 million in taxes.

Income Tax 3.63M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -58.83% in the last 52 weeks. The beta is 1.98, so 10x Genomics's price volatility has been higher than the market average.

Beta (5Y) 1.98
52-Week Price Change -58.83%
50-Day Moving Average 8.61
200-Day Moving Average 14.29
Relative Strength Index (RSI) 54.18
Average Volume (20 Days) 3,702,128

Short Selling Information

The latest short interest is 14.88 million, so 12.08% of the outstanding shares have been sold short.

Short Interest 14.88M
Short Previous Month 15.50M
Short % of Shares Out 12.08%
Short % of Float 13.65%
Short Ratio (days to cover) 3.56

Income Statement

In the last 12 months, 10x Genomics had revenue of $624.66 million and -$157.04 million in losses. Loss per share was -$1.30.

Revenue 624.66M
Gross Profit 427.01M
Operating Income -181.59M
Pretax Income -233.22M
Net Income -157.04M
EBITDA -146.88M
EBIT -181.59M
Loss Per Share -$1.30
Full Income Statement

Balance Sheet

The company has $426.91 million in cash and $80.07 million in debt, giving a net cash position of $346.83 million or $2.82 per share.

Cash & Cash Equivalents 426.91M
Total Debt 80.07M
Net Cash 346.83M
Net Cash Per Share $2.82
Equity (Book Value) 706.90M
Book Value Per Share 5.74
Working Capital 471.83M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $56.74 million and capital expenditures -$11.38 million, giving a free cash flow of $45.36 million.

Operating Cash Flow 56.74M
Capital Expenditures -11.38M
Free Cash Flow 45.36M
FCF Per Share $0.37
Full Cash Flow Statement

Margins

Gross margin is 68.36%, with operating and profit margins of -29.07% and -25.14%.

Gross Margin 68.36%
Operating Margin -29.07%
Pretax Margin -24.56%
Profit Margin -25.14%
EBITDA Margin -23.51%
EBIT Margin -29.07%
FCF Margin 7.26%

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -2.66%
Shareholder Yield -2.66%
Earnings Yield -13.95%
FCF Yield 4.03%
Dividend Details

Analyst Forecast

The average price target for 10x Genomics is $15.81, which is 70.92% higher than the current price. The consensus rating is "Buy".

Price Target $15.81
Price Target Difference 70.92%
Analyst Consensus Buy
Analyst Count 15
Revenue Growth Forecast (5Y) 6.68%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

10x Genomics has an Altman Z-Score of 5.27 and a Piotroski F-Score of 5.

Altman Z-Score 5.27
Piotroski F-Score 5